Evaluating CHT102 for treating advanced solid tumors with mesothelin expression

A Clinical Study of CHT102, a Universal Chimeric Antigen Receptor T-Cell Immunotherapy(U CAR-T) for Mesothelin(MSLN) Positive Advanced Solid Tumors: a Single-arm, Open-label, Dose Escalation and Expansion Clinical Study

This study is testing a new immune therapy called CHT102 to see if it can help adults with advanced solid tumors that have the mesothelin protein and haven't responded to other treatments.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 24 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Tianjin Medical University Cancer Institute and Hospital (other)
• Drugs / interventions: CAR-T, chemotherapy, prednisone, Chimeric Antigen Receptor, Immunotherapy
• Locations: 1 site (Tianjin, Tianjin Municipality)
• Trial ID: NCT06717022 on ClinicalTrials.gov

What this trial studies

This clinical study aims to assess the safety and efficacy of CHT102, a Universal Chimeric Antigen Receptor T-Cell Immunotherapy, specifically targeting mesothelin-positive advanced solid tumors. Participants will include adults with confirmed advanced or metastatic solid tumors that have either failed standard first-line therapy or have no recommended treatment options. The study will involve administering allogeneic CAR T cells and monitoring the patients for treatment outcomes and side effects.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with mesothelin-positive advanced or metastatic solid tumors that have not responded to standard treatments.

Not a fit: Patients with tumors that do not express mesothelin or those who have not yet received standard first-line therapy may not benefit from this study.

Why it matters

Potential benefit: If successful, this therapy could provide a new treatment option for patients with advanced solid tumors that express mesothelin.

How similar studies have performed: While the specific approach of using CHT102 is novel, similar CAR-T therapies targeting other antigens have shown promise in treating various cancers.

Eligibility criteria

Inclusion Criteria:

* Ability to understand and sign a written informed consent document；
* Age ≥18 years old, male or female；
* Histopathological confirmed advanced or metastatic solid tumors failed to at least standard first-line therapy or initially diagnosed advanced solid tumors that have no National Comprehensive Cancer Network (NCCN ）guideline recommended standard first-line therapy；
* Histopathology or cytology (paraffin section or fresh biopsy tumor tissue specimen) diagnosed as advanced/metastatic solid tumor (positive tumor MSLN expression (tumor MSLN positive (IHC 2+) confirmed by histology or pathology));
* At least one measurable lesion at baseline per RECIST version 1.1；
* The expected survival time is more than 12 weeks;
* ECOG(American Eastern Oncology Consortium) 0-1 points;
* The function of important organs is basically normal;
* The investigator determines that the patient must have fully recovered from previous treatment toxicity to ≤ grade 1, except in the following cases: a. Hair loss; b. Pigmentation; c. Long-term toxicity caused by radiotherapy, which could not be recovered according to the investigators; d. Platinum induced grade 2 or lower neurotoxicity (CTCAE 5.0);
* Subjects agree to use reliable and effective contraceptive methods for contraception within
* 6 months after signing the informed consent form to receiving CAR-T cell infusion (excluding rhythm contraception).

Exclusion Criteria:

* Received any experimental drug treatment or used experimental devices within 28 days;
* Received anti-tumor therapy such as chemotherapy and targeted therapy within 4 weeks;
* Received cell therapy products other than MSLN targets within 1 month;
* Patients who have previously received other cell therapy products should be tested for RCL(Replication Competent Retrovirus ) during the screening period if any test result is positive;
* Received chemotherapy other than lymphocyte clearance chemotherapy within 14 days prior to CHT102 infusion;
* Received systemic corticosteroid therapy at doses greater than 10 mg/day prednisone (or equivalent doses of other corticosteroids) within 2 weeks；
* Patients receiving oral or intravenous anticoagulant therapy within 7 days prior to CHT102 cell infusion;
* Prior organ allograft transplantations or allogeneic hematopoietic stem cell transplantation;
* Patients with immune deficiency or autoimmune diseases, or who require immunosuppressants;
* Vaccination within 14 days of study enrollment, or who required live vaccine immunization during the study period;
* Active/symptomatic central nervous system metastases or meningeal metastases at the time of screening; subjects with brain metastases who have been treated must be confirmed to have no imaging evidence of progression ≥ 4 weeks after the end of treatment before they can be enrolled;
* Serious or uncontrollable systemic disease or any unstable systemic disease, including but not limited to uncontrolled hypertension, uncontrolled hyperglycemia, liver and kidney insufficiency or metabolic disease, central nervous system disease, etc;
* Have any of the following heart conditions:
* New York Heart Association (NYHA) stage III or IV congestive heart failure;
* Myocardial infarction or coronary artery bypass grafting (CABG) within 6 months before enrollment;
* Clinically significant ventricular arrhythmia,
* echocardiography showed cardiac ejection fraction\<50%, QTc (male)\>450 ms，QTc (female)\>470 ms；;
* Pregnant, lactating, or breastfeeding females;
* Patients with poor control of thoracoabdominal water;
* Other investigators deem it inappropriate to participate in the study.

Where this trial is running

Tianjin, Tianjin Municipality

• Tianjin Medical University Cancer Institute & Hospital — Tianjin, Tianjin Municipality, China (RECRUITING)

Conditions: Mesothelin Positive Tumors, CHT102, a U CAR-T therapy for MSLN-positive advanced solid tumors